Cargando…
Novel Molecular Therapeutics Targeting Signaling Pathway to Control Hepatitis B Viral Infection
Numerous canonical cellular signaling pathways modulate hepatitis B virus (HBV) replication. HBV genome products are known to play a significant role in regulating these cellular pathways for the liver’s viral-related pathology and physiology and have been identified as the main factor in hepatocarc...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894711/ https://www.ncbi.nlm.nih.gov/pubmed/35252042 http://dx.doi.org/10.3389/fcimb.2022.847539 |
_version_ | 1784662743073161216 |
---|---|
author | Yan, Yan Qiu, Yuanwang Davgadorj, Chantsalmaa Zheng, Chunfu |
author_facet | Yan, Yan Qiu, Yuanwang Davgadorj, Chantsalmaa Zheng, Chunfu |
author_sort | Yan, Yan |
collection | PubMed |
description | Numerous canonical cellular signaling pathways modulate hepatitis B virus (HBV) replication. HBV genome products are known to play a significant role in regulating these cellular pathways for the liver’s viral-related pathology and physiology and have been identified as the main factor in hepatocarcinogenesis. Signaling changes during viral replication ultimately affect cellular persistence, multiplication, migration, genome instability, and genome damage, leading to proliferation, evasion of apoptosis, block of differentiation, and immortality. Recent studies have documented that numerous signaling pathway agonists or inhibitors play an important role in reducing HBV replication in vitro and in vivo, and some have been used in phase I or phase II clinical trials. These optional agents as molecular therapeutics target cellular pathways that could limit the replication and transcription of HBV or inhibit the secretion of the small surface antigen of HBV in a signaling-independent manner. As principle-based available information, a combined strategy including antiviral therapy and immunomodulation will be needed to control HBV infection effectively. In this review, we summarize recent findings on interventions of molecular regulators in viral replication and the interactions of HBV proteins with the components of the various targeting cellular pathways, which may assist in designing novel agents to modulate signaling pathways to prevent HBV replication or carcinogenesis. |
format | Online Article Text |
id | pubmed-8894711 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88947112022-03-05 Novel Molecular Therapeutics Targeting Signaling Pathway to Control Hepatitis B Viral Infection Yan, Yan Qiu, Yuanwang Davgadorj, Chantsalmaa Zheng, Chunfu Front Cell Infect Microbiol Cellular and Infection Microbiology Numerous canonical cellular signaling pathways modulate hepatitis B virus (HBV) replication. HBV genome products are known to play a significant role in regulating these cellular pathways for the liver’s viral-related pathology and physiology and have been identified as the main factor in hepatocarcinogenesis. Signaling changes during viral replication ultimately affect cellular persistence, multiplication, migration, genome instability, and genome damage, leading to proliferation, evasion of apoptosis, block of differentiation, and immortality. Recent studies have documented that numerous signaling pathway agonists or inhibitors play an important role in reducing HBV replication in vitro and in vivo, and some have been used in phase I or phase II clinical trials. These optional agents as molecular therapeutics target cellular pathways that could limit the replication and transcription of HBV or inhibit the secretion of the small surface antigen of HBV in a signaling-independent manner. As principle-based available information, a combined strategy including antiviral therapy and immunomodulation will be needed to control HBV infection effectively. In this review, we summarize recent findings on interventions of molecular regulators in viral replication and the interactions of HBV proteins with the components of the various targeting cellular pathways, which may assist in designing novel agents to modulate signaling pathways to prevent HBV replication or carcinogenesis. Frontiers Media S.A. 2022-02-18 /pmc/articles/PMC8894711/ /pubmed/35252042 http://dx.doi.org/10.3389/fcimb.2022.847539 Text en Copyright © 2022 Yan, Qiu, Davgadorj and Zheng https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cellular and Infection Microbiology Yan, Yan Qiu, Yuanwang Davgadorj, Chantsalmaa Zheng, Chunfu Novel Molecular Therapeutics Targeting Signaling Pathway to Control Hepatitis B Viral Infection |
title | Novel Molecular Therapeutics Targeting Signaling Pathway to Control Hepatitis B Viral Infection |
title_full | Novel Molecular Therapeutics Targeting Signaling Pathway to Control Hepatitis B Viral Infection |
title_fullStr | Novel Molecular Therapeutics Targeting Signaling Pathway to Control Hepatitis B Viral Infection |
title_full_unstemmed | Novel Molecular Therapeutics Targeting Signaling Pathway to Control Hepatitis B Viral Infection |
title_short | Novel Molecular Therapeutics Targeting Signaling Pathway to Control Hepatitis B Viral Infection |
title_sort | novel molecular therapeutics targeting signaling pathway to control hepatitis b viral infection |
topic | Cellular and Infection Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894711/ https://www.ncbi.nlm.nih.gov/pubmed/35252042 http://dx.doi.org/10.3389/fcimb.2022.847539 |
work_keys_str_mv | AT yanyan novelmoleculartherapeuticstargetingsignalingpathwaytocontrolhepatitisbviralinfection AT qiuyuanwang novelmoleculartherapeuticstargetingsignalingpathwaytocontrolhepatitisbviralinfection AT davgadorjchantsalmaa novelmoleculartherapeuticstargetingsignalingpathwaytocontrolhepatitisbviralinfection AT zhengchunfu novelmoleculartherapeuticstargetingsignalingpathwaytocontrolhepatitisbviralinfection |